Empirical Wealth Management
ACAD icon

Empirical Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Empirical Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$546K Buy
27,094
+11,605
+75% +$312K 0.01% 737
2026
Q2 		$392K Buy
15,489
+2,566
+20% +$56.5K 0.01% 783
2026
Q1 		$288K Buy
12,923
+3,026
+31% +$72.3K 0.01% 810
2025
Q4 		$264K Buy
+9,897
New +$237K ﹤0.01% 744

Other funds holding ACAD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Empirical Wealth Management's ACAD Position: Q3 2026 in Review

Empirical Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 75% in Q3 2026, buying an estimated $312K and bringing the position to 27,094 shares worth $546K. The position accounts for 0.01% of the portfolio, ranked #737.

Empirical Wealth Management first reported a position in ACAD in Q4 2025 and has held it in 4 quarters since. 111 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Empirical Wealth Management held 27,094 shares of Acadia Pharmaceuticals worth $546K as of Q3 2026.
  • Empirical Wealth Management bought 11,605 Acadia Pharmaceuticals shares in Q3 2026, an estimated $312K.
  • Acadia Pharmaceuticals made up 0.01% of Empirical Wealth Management's portfolio in Q3 2026, its #737 holding.
  • Empirical Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 111 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Empirical Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.